194 related articles for article (PubMed ID: 24011220)
1. Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study.
Zettl UK; Bauer-Steinhusen U; Glaser T; Hechenbichler K; Limmroth V;
BMC Neurol; 2013 Sep; 13():117. PubMed ID: 24011220
[TBL] [Abstract][Full Text] [Related]
2. Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary.
Zettl UK; Bauer-Steinhusen U; Glaser T; Czekalla J; Hechenbichler K; Limmroth V; Hecker M
Adv Ther; 2016 May; 33(5):834-47. PubMed ID: 27090116
[TBL] [Abstract][Full Text] [Related]
3. The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicentric cross-sectional survey in the western Balkan countries.
Drulovic J; Cukic M; Grgic S; Dincic E; Raicevic R; Nadj C; Toncev G; Vojinovic S; Mesaros S; Kisic Tepavcevic D; Dujmovic I; Tadic D; Miletic-Drakulic S; Dackovic J; Kostic S; Erakovic J; Sakalas L; Savic D; Suknjaja V; Martinovic V; Maric G; Pekmezovic T
Mult Scler Relat Disord; 2017 Jan; 11():56-61. PubMed ID: 28104258
[TBL] [Abstract][Full Text] [Related]
4. Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study.
Kleiter I; Lang M; Jeske J; Norenberg C; Stollfuß B; Schürks M
BMC Neurol; 2017 Sep; 17(1):174. PubMed ID: 28877664
[TBL] [Abstract][Full Text] [Related]
5. Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study.
Lugaresi A; Florio C; Brescia-Morra V; Cottone S; Bellantonio P; Clerico M; Centonze D; Uccelli A; di Ioia M; De Luca G; Marcellusi A; Paolillo A;
BMC Neurol; 2012 Mar; 12():7. PubMed ID: 22390218
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Medication Adherence Using a Medical App Among Patients With Multiple Sclerosis Treated With Interferon Beta-1b: Pilot Digital Observational Study (PROmyBETAapp).
Limmroth V; Hechenbichler K; Müller C; Schürks M
J Med Internet Res; 2019 Jul; 21(7):e14373. PubMed ID: 31359863
[TBL] [Abstract][Full Text] [Related]
7. Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis.
Zettl UK; Schreiber H; Bauer-Steinhusen U; Glaser T; Hechenbichler K; Hecker M;
Acta Neurol Scand; 2017 Aug; 136(2):116-121. PubMed ID: 27796033
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study.
Patti F; Penaherrera JN; Zieger L; Wicklein EM
BMC Neurol; 2021 Aug; 21(1):324. PubMed ID: 34425763
[TBL] [Abstract][Full Text] [Related]
9. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis.
Mohr DC; Goodkin DE; Likosky W; Gatto N; Baumann KA; Rudick RA
Arch Neurol; 1997 May; 54(5):531-3. PubMed ID: 9152109
[TBL] [Abstract][Full Text] [Related]
10. Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.
Hoffmann FA; Trenova A; Llaneza MA; Fischer J; Lus G; von Bredow D; Lara N; Lam E; Van Hoef M; Bakshi R
BMC Neurol; 2017 Aug; 17(1):156. PubMed ID: 28793876
[TBL] [Abstract][Full Text] [Related]
11. Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis.
Turner AP; Williams RM; Sloan AP; Haselkorn JK
Rehabil Psychol; 2009 Feb; 54(1):116-21. PubMed ID: 19618711
[TBL] [Abstract][Full Text] [Related]
12. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
Durelli L; Verdun E; Barbero P; Bergui M; Versino E; Ghezzi A; Montanari E; Zaffaroni M;
Lancet; 2002 Apr; 359(9316):1453-60. PubMed ID: 11988242
[TBL] [Abstract][Full Text] [Related]
13. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
[TBL] [Abstract][Full Text] [Related]
14. Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).
Jongen PJ; Hengstman G; Hupperts R; Schrijver H; Gilhuis J; Vliegen JH; Hoogervorst E; van Huizen M; van Munster E; Samijn J; de Schryver E; Siepman T; Tonk M; Zandbergen E; ten Holter J; van der Kruijk R; Borm G
BMC Neurol; 2011 Mar; 11():40. PubMed ID: 21450086
[TBL] [Abstract][Full Text] [Related]
15. Supportive strategies to improve adherence to IFN β-1b in multiple sclerosis--results of the βPlus observational cohort study.
Pozzilli C; Schweikert B; Ecari U; Oentrich W;
J Neurol Sci; 2011 Aug; 307(1-2):120-6. PubMed ID: 21636099
[TBL] [Abstract][Full Text] [Related]
16. Improving compliance with interferon-beta therapy in patients with multiple sclerosis.
Portaccio E; Amato MP
CNS Drugs; 2009; 23(6):453-62. PubMed ID: 19480465
[TBL] [Abstract][Full Text] [Related]
17. Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations.
Bagnato F; Gupta S; Richert ND; Stone RD; Ohayon JM; Frank JA; McFarland HF
Arch Neurol; 2005 Nov; 62(11):1684-8. PubMed ID: 16157739
[TBL] [Abstract][Full Text] [Related]
18. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
19. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low.
Wong J; Gomes T; Mamdani M; Manno M; O'Connor PW
Can J Neurol Sci; 2011 May; 38(3):429-33. PubMed ID: 21515501
[TBL] [Abstract][Full Text] [Related]
20. [Current status of interferon beta-1b in multiple sclerosis therapy].
Hartung HP
Med Klin (Munich); 2001 Sep; 96 Suppl 1():11-6. PubMed ID: 11603110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]